About ImmunoBiology
ImmunoBiology is a company based in Babraham (United Kingdom) founded in 2003 by Camilo Colaco. ImmunoBiology has raised $1.18 million across 4 funding rounds from investors including European Union. The company has 3 employees as of May 31, 2022. ImmunoBiology operates in a competitive market with competitors including Insmed, VBI Vaccines, Affinivax, Imvax and Eligo Bioscience, among others.
- Headquarter Babraham, United Kingdom
- Employees 3 as on 31 May, 2022
- Founders Camilo Colaco
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immunobiology Limited
- Date of Incorporation 26 May, 1999
- Jurisdiction CAMBRIDGE
-
Annual Revenue
$584.69 K (USD)0as on May 31, 2019
-
Net Profit
-$632.32 K (USD)-207as on May 31, 2020
-
EBITDA
-$748.68 K (USD)-93as on May 31, 2020
-
Total Equity Funding
$1.18 M (USD)
in 4 rounds
-
Latest Funding Round
$193.26 K (USD), Unspecified
Feb 07, 2020
- Investors
-
Employee Count
3
as on May 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ImmunoBiology
ImmunoBiology has successfully raised a total of $1.18M across 4 strategic funding rounds. The most recent funding activity was a Unspecified round of $193.26 thousand completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ImmunoBiology
ImmunoBiology has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for ImmunoBiology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ImmunoBiology
Investment portfolio details for ImmunoBiology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ImmunoBiology
Detailed financials for ImmunoBiology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immunobiology Comparisons
Peer comparison for ImmunoBiology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ImmunoBiology
ImmunoBiology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, VBI Vaccines, Affinivax, Imvax and Eligo Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
VBI Vaccines is engaged in developing vaccines and immunotherapeutics.
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Patient-specific cell vaccines for glioma treatment are developed.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| Locked | Locked | Locked |
Provider of human monoclonal antibodies against infectious diseases
|
Detailed competitors of ImmunoBiology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immunobiology
Complete news archive for ImmunoBiology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImmunoBiology
ImmunoBiology was founded in 2003 and raised its 1st funding round 13 years after it was founded.
ImmunoBiology is headquartered in Babraham, United Kingdom. It is registered at Babraham, Cambridgeshire, United Kingdom.
ImmunoBiology is a funded company, having raised a total of $1.18M across 4 funding rounds to date.
As of May 31, 2022, the latest employee count at ImmunoBiology is 3.
Annual revenue of ImmunoBiology is $584.69K as on May 31, 2019.
The company was founded in 2003 in Babraham, United Kingdom, and operates in the biotechnology sector focused on vaccine development. Proprietary ImmBioVax platforms are utilized to target bacterial pathogens, addressing conditions such as pneumococcal disease, meningitis, and tuberculosis. Specific products include PnuBioVax for invasive pneumococcal disease, MenBioVax for meningococcal disease, T-BioVax for tuberculosis, along with candidates against Helicobacter pylori and Clostridium difficile.
ImmunoBiology's top competitors include Imvax, VBI Vaccines and Aridis Pharma.
ImmunoBiology has 1 investor. Key investors include European Union.